- |||||||||| AiRuiKang (dalpiciclib) / Jiangsu Hengrui Pharma, Irene (pyrotinib) / Jiangsu Hengrui Pharma
Trial primary completion date, Combination therapy, Metastases: PLEASURABLE: Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer (clinicaltrials.gov) - Dec 10, 2019 P1/2, N=32, Recruiting, Whilst we cannot influence the oestradiol concentration in Letrozole cycles, if the oestradiol is < 400 pmol, patients can be counselled accordingly and may elect not to proceed with IUI, especially if they are paying for treatment themselves. Trial primary completion date: Nov 2019 --> Jun 2020
- |||||||||| Ibrance (palbociclib) / Pfizer
Journal: Analysis of the selection of CDK4/6 inhibitors based on experience using palbociclib. (Pubmed Central) - Dec 8, 2019 When the number of neutrophils prior to palbociclib introduction was <3,000, neutropenia of grade 3 or higher was observed in all cases following palbociclib introduction. Thus, in order to avoid grade 3 or higher neutropenia and to maintain relative dose intensity, abemaciclib treatment may be considered for cases with neutrophils of <3,000 prior to the introduction of a CDK4/6 inhibitor.
- |||||||||| Review, Journal: Pharmacology of medications used for ovarian stimulation. (Pubmed Central) - Nov 30, 2019
The pharmacology of all current major medications used to stimulate ovarian function is reviewed in this article, including letrozole, clomiphene citrate, gonadotropins, and pulsatile gonadotropin releasing hormone (GnRH). Novel potential compounds and adjuvant treatment approaches are also discussed, such as kisspeptin agonists and androgens.
- |||||||||| Ibrance (palbociclib) / Pfizer
Clinical, Clinical data, Review, Journal, Real-world evidence: Real-world clinical outcomes and toxicity in metastatic breast cancer patients treated with palbociclib and endocrine therapy. (Pubmed Central) - Nov 29, 2019 Among patients with HR-positive advanced breast cancer, the estimated PFS in patients treated with fulvestrant and palbociclib was comparable to a previously reported phase 3 trial. However, the median PFS with letrozole and palbociclib was shorter than previously reported data from phase 2 and 3 trials. Palbociclib toxicity was very manageable, with a low drug discontinuation rate.
- |||||||||| Ibrance (palbociclib) / Pfizer
Enrollment change, Trial completion date, Trial primary completion date: Palbociclib and FES PET (clinicaltrials.gov) - Nov 27, 2019 P2, N=30, Active, not recruiting, L-based therapy is an active therapeutic option and remains a viable option for HER2 + MBC after prior trastuzumab, P and/or T-DM1. N=15 --> 30 | Trial completion date: Nov 2019 --> May 2020 | Trial primary completion date: Nov 2019 --> May 2020
- |||||||||| Ibrance (palbociclib) / Pfizer
New trial, HEOR, Combination therapy, Real-world evidence, Real-world, Metastases: Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy (clinicaltrials.gov) - Nov 24, 2019 P, N=1, Active, not recruiting,
- |||||||||| Herceptin (trastuzumab) / Roche
CARDIAC TOXICITY OF ADJUVANT TRASTUZUMAB IN BREAST CANCER PATIENTS AGED ⩾60 YEARS () - Nov 23, 2019 - Abstract #AIOM2019AIOM_76; Our results show that, with appropriate pts selection and systematic cardiac assessment, cardiotoxicity in adjuvant trastuzumab therapy is confirmed manageable also in older women. In our experience no serious cardiac events were observed and only 5.3% of pts permanently discontinued treatment because of cardiac toxicity.
- |||||||||| letrozole / generics
EFFICACY AND SAFETY OF RIBOCLICLIB AND LETROZOLE IN THE TREATMENT OF LOCALLY ADVANCED AND METASTATIC HR+/HER2 - BREAST CANCER: A REAL WORLD EXPERIENCE () - Nov 23, 2019 - Abstract #AIOM2019AIOM_75; This therapeutic approach translates into the possibility of administering to women in this setting a treatment that is not, as a first option,chemotherapy, but an oral therapy, with many advantages for patients in terms of quality of life, impact on everyday life and safety. These results, confirmed in our real life experience,open up new horizons, not only for the efficacy observed, but also for the quality of life that this change can offer.
- |||||||||| Kisqali (ribociclib) / Novartis
Clinical, FDA event, Journal: FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer. (Pubmed Central) - Nov 22, 2019 The most common adverse reactions observed in 20% or more of patients taking ribociclib were neutropenia, nausea, fatigue, diarrhea, leukopenia, alopecia, vomiting, constipation, headache, and back pain. This article summarizes FDA decision-making and data supporting the approval of ribociclib.
- |||||||||| Piqray (alpelisib) / Novartis, Kisqali (ribociclib) / Novartis
Trial primary completion date, Metastases: CLEE011X2107: Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer (clinicaltrials.gov) - Nov 20, 2019 P1, N=256, Active, not recruiting, Exemestane is less detrimental to bone health than letrozole in postmenopausal women treated with AI, and this effect may be confined to patients carrying UGT2B17*2, though this finding requires independent validation. Trial primary completion date: Nov 2020 --> Nov 2019
- |||||||||| letrozole / generics
Preclinical, Journal: Effect of electroacupuncture at different acupoints on follicle development and related factors in serum and ovary tissues of PCOS rats (Pubmed Central) - Nov 18, 2019 EA of CV4, SP6, ST36 and ST36+CV4+SP6 can reduce the number of follicles at the growth stage and regulate the expression levels of gonadotropins in PCOS rats. The effects of EA of CV4 and ST36 are evidently better than those of EA of SP6 in up-regulating serum FSH content and in down-regulating LH/FSH ratio, and serum AMH and INHB levels, and EA of SP6 is evidently superior to EA of CV4 down-regulating LH level, but without synergistic effect among the 3 acupoints.
- |||||||||| everolimus / Generic mfg.
Trial completion date, Trial primary completion date: Phase II Study of Everolimus Beyond Progression (clinicaltrials.gov) - Nov 15, 2019 P2, N=3, Active, not recruiting, The effects of EA of CV4 and ST36 are evidently better than those of EA of SP6 in up-regulating serum FSH content and in down-regulating LH/FSH ratio, and serum AMH and INHB levels, and EA of SP6 is evidently superior to EA of CV4 down-regulating LH level, but without synergistic effect among the 3 acupoints. Trial completion date: Oct 2020 --> Nov 2021 | Trial primary completion date: Oct 2019 --> Nov 2020
|